Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Okayama, Japan
NCT Number: NCT01170377
The aim of this study is to evaluate the effect of valproate on the required dose of propofol for sedation in patients with mental retardation.
Looking for future studies?
Notify Me16 year and older
All sexes
Observational
Okayama, Japan
The intravenous sedation with propofol is very useful for patients with mental retardation and challenging behavior. However, it is very difficult to titrate the dose of propofol for maintaining the adequate sedation depth because of the difficulty of verbal communication with them. Most of them have a epilepsy and take antiepileptic drugs. Antiepileptic drugs are thought to influence on the effect of anesthetics. Valproate is reported to inhibit the metabolism of propofol. Therefore, we divide the patients into two groups : patients receiving valproate (valproate group), patients receiving no antiepileptic drugs (control group), and compare the required dose of propofol and the recovery time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 day
Time frame: 1 day
Time frame: 1 day
Okayama University
Other
The Effect of Valproate on the Required Dose of Propofol for Sedation in Patients With Mental Retardation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01031407
Adult, Asperger Syndrome
Bethesda, Maryland, United States
View Trial DetailsNCT01043198
Body Weight, Chromosome Aberrations
Bordeaux, France
View Trial DetailsNCT03503955
Intellectual Disability, Mental Disorders
Istanbul, Bakırköy, Turkey (Türkiye)
View Trial DetailsNCT02791321
Autism Spectrum Disorder, Child Development Disorders, Pervasive
Montpellier, France
View Trial Details